Gregg Lucksinger

709 total citations
5 papers, 109 citations indexed

About

Gregg Lucksinger is a scholar working on Epidemiology, Infectious Diseases and Microbiology. According to data from OpenAlex, Gregg Lucksinger has authored 5 papers receiving a total of 109 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Epidemiology, 3 papers in Infectious Diseases and 2 papers in Microbiology. Recurrent topics in Gregg Lucksinger's work include Influenza Virus Research Studies (2 papers), Herpesvirus Infections and Treatments (2 papers) and SARS-CoV-2 and COVID-19 Research (1 paper). Gregg Lucksinger is often cited by papers focused on Influenza Virus Research Studies (2 papers), Herpesvirus Infections and Treatments (2 papers) and SARS-CoV-2 and COVID-19 Research (1 paper). Gregg Lucksinger collaborates with scholars based in United States, Switzerland and Denmark. Gregg Lucksinger's co-authors include Casey Johnson, Scott Umlauf, Cynthia Strout, Lynda Tussey, Ge Liu, C. J. White, Matthew Davis, Langzhou Song, Judith Absalon and John L. Perez and has published in prestigious journals such as The Journal of Infectious Diseases, Vaccine and Human Vaccines & Immunotherapeutics.

In The Last Decade

Gregg Lucksinger

5 papers receiving 108 citations

Peers

Countries citing papers authored by Gregg Lucksinger

Since Specialization

Citations

This map shows the geographic impact of Gregg Lucksinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregg Lucksinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregg Lucksinger more than expected).

Fields of papers citing papers by Gregg Lucksinger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gregg Lucksinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregg Lucksinger. The network helps show where Gregg Lucksinger may publish in the future.

Co-authorship network of co-authors of Gregg Lucksinger

This figure shows the co-authorship network connecting the top 25 collaborators of Gregg Lucksinger. A scholar is included among the top collaborators of Gregg Lucksinger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gregg Lucksinger. Gregg Lucksinger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

5 of 5 papers shown

#	Work	Indexed citations
1	Immunogenicity and safety of lyophilized and liquid dengue tetravalent vaccine candidate formulations in healthy adults: a randomized, phase 2 clinical trial 2020 ·Human Vaccines & Immunotherapeutics ·M. Turner, (unknown), Peter Winkle, Nathan Segall, Michael C. Levin, Matthew W. Doust, Casey Johnson, Gregg Lucksinger, Carlos Fierro, (unknown), Marsha G. Raanan, Vianney Tricou, Astrid Borkowski, Derek Wallace	24
2	Effects of Different Doses of GEN-003, a Therapeutic Vaccine for Genital Herpes Simplex Virus-2, on Viral Shedding and Lesions: Results of a Randomized Placebo-Controlled Trial 2018 ·The Journal of Infectious Diseases ·Nicholas Van Wagoner, Kenneth H. Fife, Peter A. Leone, David I. Bernstein, Terri Warren, Lori Panther, Richard M. Novak, Richard H. Beigi, John D. Kriesel, Stephen K. Tyring, William Koltun, Gregg Lucksinger, Amy Morris, Bin Zhang, Lisa K. McNeil, Sybil Tasker, Seth Hetherington, Anna Wald	31
3	A phase 3, randomized, active-controlled study to assess the safety and tolerability of meningococcal serogroup B vaccine bivalent rLP2086 in healthy adolescents and young adults 2016 ·Vaccine ·Lars Østergaard, Gregg Lucksinger, Judith Absalon, Johannes Beeslaar, Joseph J. Eiden, Kathrin U. Jansen, Laura J. York, (unknown), (unknown), John L. Perez	19
4	Phase 1 Safety and Immunogenicity Study of a Quadrivalent Seasonal Flu Vaccine Comprising Recombinant Hemagglutinin-Flagellin Fusion Proteins 2016 ·Open Forum Infectious Diseases ·Lynda Tussey, Cynthia Strout, Matthew Davis, Casey Johnson, Gregg Lucksinger, Scott Umlauf, Langzhou Song, Ge Liu, (unknown), C. J. White	31
5	GEN-003 Phase 2 Interim Results: Therapeutic Vaccine for Genital Herpes Significantly Reduces Viral Shedding and Genital Lesions 2015 ·Open Forum Infectious Diseases ·Nicholas Van Wagoner, William Koltun, Gregg Lucksinger, Terri Warren, Stephen K. Tyring, David Bernstein, Peter A. Leone, Lori Panther, Jacob Lalezari, Kenneth H. Fife, Richard Novák, Richard H. Beigi, John D. Kriesel, Jason Chan, Sybil Tasker, Seth Hetherington, Anna Wald	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact